Saurat J H, Mérot Y, Borsky M, Abba Z, Hirschel-Scholz S
Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève, Suisse.
Dermatologica. 1988;176(4):191-9. doi: 10.1159/000248702.
Ro 13-7410 was given to 29 patients (a total of 38 treatment courses) for 7.5 weeks (range 4-23). This compound is one of the most potent retinoids ever synthetized and has the highest affinity to human skin cellular retinoic-acid-binding protein. At therapeutically active doses, it did not induce the commonly seen mucocutaneous signs of retinoid toxicity such as scaling and cheilitis; over 0.5 microgram/kg body weight/day, it very frequently induced an eczematous retinoid dermatitis. This pilot study provides some indications on what appears to be in several aspects a drug quite distinct from retinoids previously used in humans.
将Ro 13-7410给予29例患者（共38个疗程），持续7.5周（范围4 - 23周）。该化合物是合成的最强效类维生素A之一，对人皮肤细胞视黄酸结合蛋白具有最高亲和力。在治疗活性剂量下，它不会诱发类维生素A毒性常见的皮肤黏膜症状，如脱屑和唇炎；超过0.5微克/千克体重/天，它很频繁地诱发湿疹样类维生素A皮炎。这项初步研究在几个方面对一种似乎与先前用于人类的类维生素A截然不同的药物提供了一些线索。
